In a report released today, Alex Arfaei from BMO Capital maintained a Sell rating on AbbVie (NYSE: ABBV), with a price target of $78. The company’s shares opened today at $91.71.
According to TipRanks.com, Arfaei is a 4-star analyst with an average return of 8.0% and a 71.6% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and Bristol Myers.
The word on The Street in general, suggests a Hold analyst consensus rating for AbbVie with a $97.17 average price target.
See today’s analyst top recommended stocks >>
Based on AbbVie’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $8.28 billion and net profit of $1.97 billion. In comparison, last year the company earned revenue of $6.94 billion and had a net profit of $1.91 billion.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
